000			02220 a2200589 4500
005			20250516091757.0
264		0	_c20130418
008			201304s 0 0 eng d
022			_a1463-1326
024	7		_a10.1111/j.1463-1326.2012.01618.x _2doi
040			_aNLM _beng _cNLM
100	1		_aSeino, Y
245	0	0	_aRandomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). _h[electronic resource]
260			_bDiabetes, obesity & metabolism _cOct 2012
300			_a910-7 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAsian People
650	0	4	_aBlood Glucose
650	0	4	_aBody Mass Index
650	0	4	_aDiabetes Mellitus, Type 2 _xblood
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aGlucagon-Like Peptide-1 Receptor
650	0	4	_aGlycated Hemoglobin _xmetabolism
650	0	4	_aHumans
650	0	4	_aHypoglycemia _xblood
650	0	4	_aHypoglycemic Agents _xadministration & dosage
650	0	4	_aInsulin _xadministration & dosage
650	0	4	_aJapan _xepidemiology
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPeptides _xadministration & dosage
650	0	4	_aPhilippines _xepidemiology
650	0	4	_aPostprandial Period
650	0	4	_aReceptors, Glucagon _xantagonists & inhibitors
650	0	4	_aRepublic of Korea _xepidemiology
650	0	4	_aSulfonylurea Compounds _xadministration & dosage
650	0	4	_aTaiwan _xepidemiology
650	0	4	_aTreatment Outcome
700	1		_aMin, K W
700	1		_aNiemoeller, E
700	1		_aTakami, A
773	0		_tDiabetes, obesity & metabolism _gvol. 14 _gno. 10 _gp. 910-7
856	4	0	_uhttps://doi.org/10.1111/j.1463-1326.2012.01618.x _zAvailable from publisher's website
999			_c21761180 _d21761180